Daniel G. Bichet

Hôpital du Sacré-Cœur de Montréal — Canada

Medicine · Health Sciences

73h-index20.9kcitations392works6.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Electrolyte and hormonal disorders(149), Ion Transport and Channel Regulation(127), Lysosomal Storage Disorders Research(87), Neuroendocrine regulation and behavior(58), Ion channel regulation and function(31)

Publications392 total

Author Correction: Diabetes insipidus
Nature Reviews Disease Primers·2025Open Access
Thirsty encounters of the third kind
Kidney International·2025Open Access
International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance)
Nature Reviews Nephrology·2024· 18 citedOpen Access
Renal and multisystem effectiveness of 3.9 years of migalastat in a global real‐world cohort: Results from the <scp>followME</scp> Fabry <scp>Pathfinders</scp> registry
Journal of Inherited Metabolic Disease·2024· 15 citedOpen Access
Fabry nephropathy: a treatable cause of chronic kidney disease
Rare Disease and Orphan Drugs Journal·2024· 5 citedOpen Access
Thirst, Hunger, and Nephrogenic Diabetes Insipidus
New England Journal of Medicine·2024· 3 citedOpen Access
G protein-coupled receptor (GPCR) gene variants and human genetic disease
Critical Reviews in Clinical Laboratory Sciences·2024· 24 citedOpen Access
Initiation of pharmacologic chaperone therapy for Fabry disease in the Canadian Fabry Disease Initiative (CFDI) registry is not associated with reduction of kidney function
Molecular Genetics and Metabolism·2024· 1 cited
FollowME Fabry Pathfinders Registry: Renal effectiveness in a cohort of patients on migalastat treatment for at least three years
Molecular Genetics and Metabolism·2024
Glycosphingolipid evaluation for Fabry disease patients receiving migalastat after switching from enzyme replacement therapy
Molecular Genetics and Metabolism·2024
Eight Years of Canadian Real-World Assessment of Tolvaptan in ADPKD: C-MAJOR Study and Safety Monitoring and Distribution Program
Journal of the American Society of Nephrology·2023· 1 cited
FollowME Fabry Pathfinders Registry: Renal Effectiveness in a Cohort of Patients on Migalastat Treatment for at Least Three Years
Journal of the American Society of Nephrology·2023· 1 cited
Fabry Disease Biomarkers in Patients Switched From Enzyme-Replacement Therapy to Migalastat Oral Chaperone Therapy
Bioanalysis·2023· 1 cited
Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study
Frontiers in Medicine·2023· 13 citedOpen Access
Vasopressin and oxytocin receptors in GtoPdb v.2023.1
IUPHAR/BPS Guide to Pharmacology CITE·2023· 2 citedOpen Access
Vasopressin Use in the Support of Organ Donors: Physiological Rationale and Review of the Literature
Critical Care Explorations·2023· 9 citedOpen Access
OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD
Kidney International Reports·2023· 28 citedOpen Access
Mass Spectrometry Analysis of Globotriaosylsphingosine and Its Analogues in Dried Blood Spots
International Journal of Molecular Sciences·2023· 9 citedOpen Access
Early therapy in Fabry disease: Outcomes from the Canadian Fabry Disease Initiative (CFDI) registry
Molecular Genetics and Metabolism·2023· 1 cited
FollowME Fabry Pathfinders registry: Renal effectiveness in a multi-national, multi-center cohort of patients on migalastat treatment for at least three years
Molecular Genetics and Metabolism·2023· 2 cited
page 1 of 20Next →

Frequent Co-authors

Michèle Lonergan(11), Marie‐Françoise Arthus(9), Michel Bouvier(7), Jean-Pierre Morello(5), Virginie Bernier(5), Dominique P. Germain(5), Derralynn Hughes(5), Takuya Fujiwara(5), Lise Bankir(5), Stephen Waldek(4), William R. Wilcox(4), Kathy Nicholls(4), Raphael Schiffmann(4), Walter Rosenthal(4), Nadine Bouby(4), Goce Spasovski(3), Raymond Vanholder(3), Bruno Allolio(3), Djillali Annane(3), Steve Ball(3)